Angiotensin blockade in type 2 diabetic renal disease

Kidney International, Supplement

Volumn 62, Issue 82, 2002, Pages S61-S63

  Ruilope, Luis Miguel ^a   Luño, José ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Angiotensin converting enzyme inhibitor; Angiotensin receptor blocker; Blood pressure control; Diabetic nephropathy; Irbesartan; Losartan; Microalbuminuria; Proteinuria

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IRBESARTAN; LOSARTAN; NISOLDIPINE; PLACEBO; RAMIPRIL; TELMISARTAN; VALSARTAN; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT;

BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONFERENCE PAPER; DIABETIC NEPHROPATHY; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY INJURY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEINURIA; BLOOD PRESSURE; DISEASE COURSE; DRUG EFFECT; EVIDENCE BASED MEDICINE; METABOLISM; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT OUTCOME;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; HUMANS; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME;

EID: 0036434424     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.62.s82.12.x     Document Type: Article

References (19)

1. The Sixth Report of the Joint National Committee on Prevention: Detection, evaluation, and treatment of high blood pressure. Arch Intern Med 157:2413-2446, 1997
2. Guidelines Subcommittee: World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. J Hypertens 17:151-183, 1999
3. American Diabetes Association: Diabetic nephropathy. Diabetes Care 25(Suppl 1):585-589, 2002
4. Bakris GL, Williams M, Dworkin L, et al: Preserving renal function in adults with hypertension and diabetes: A consensus approach. Am J Kidney Dis 36:646-661, 2000
5. Kshirsagar AV, Joy MS, Hogan SL, et al: Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: A systematic overview of randomized placebo-controlled trials. Am J Kidney Dis 35:695-707, 2000
6. The ACE Inhibitors in Diabetic Nephropathy Trialist Group: Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 134:370-379, 2001
7. Jafar TH, Schmid CH, Landa M, et al: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient level data. Ann Intern Med 135:73-78, 2001
8. Ravid M, Lang R, Rachmani R, Lischner M: Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin dependent diabetes mellitus: A 7-year follow-up study. Arch Intern Med 156:286-289, 1996
9. Parving HH, Hovind P, Rossing K, et al: Evolving strategies for renoprotection: Diabetic nephropathy. Curr Opin Nephrol Hypertens 10:515-522; 2001
10. Heart OPE (HOPE) Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253-259, 2000
11. Brenner BM, Cooper ME, De Zeeuw D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
12. Lewis ED, Hunsicker LG, Clarke WR, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
13. Parving H-H, Lehnert H, Bröchner-Mortensen J, et al: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878, 2001
14. Schrier RW, Estacio RO, Esler A, Mehler P: Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 61:1086-1097, 2001
15. Remuzzi G, Schieppati A, Ruggenenti P: Nephropathy in patients with type 2 diabetes. N Eng J Med 346:1145-1151, 2002
16. Chalmers JP: Ongoing trials of angiotensin-converting enzyme inhibition: What they can tell us. Am J Hypertens 14(Suppl):270S-275S, 2001
17. Weber M: Angiotensin II receptor blockers and cardiovascular outcomes: The evidence now and in the future. JRAAS 2(Suppl 2):S12-S16, 2001
18. Dahlöf B, Devereux RB, Julius S, et al: Characteristics of 9194 patients with left ventricular hypertrophy. The LIFE study. Hypertension 32:989-997, 1998
19. Kjeldsen SE, Julius S, Brunner H, et al: Characteristics of 15314 hypertensive patients at high coronary risk. The VALUE trial. Blood Press 10:83-91, 2001